<DOC>
	<DOCNO>NCT01227265</DOCNO>
	<brief_summary>This study efficacy safety preladenant adult participant moderate severe Parkinson 's Disease ( PD ) . While study , participant continue take usual , prescribed , stable regimen levodopa ( L-dopa ) L-dopa plus adjunct PD medication randomize receive 2 mg preladenant , 5 mg preladenant , placebo , twice daily , 12 week . After , participant may choose receive additional treatment preladenant . The primary hypothesis least 5 mg twice daily dose preladenant superior placebo measure change Baseline Week 12 mean `` '' time .</brief_summary>
	<brief_title>Placebo Controlled Study Preladenant Participants With Moderate Severe Parkinson 's Disease ( P07037 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Each participant must diagnosis idiopathic Parkinson 's disease . Each participant must receive prior therapy Ldopa approximately 1 year immediately Screening must continue beneficial clinical response Ldopa . Each participant must stable dopaminergic treatment regimen least 5 week immediately Randomization . Participants receive adjunctive treatment ( eg , dopamine agonist , anticholinergic ) permit enroll trial . Participants take Ldopa permit enroll trial . Each participant must experience motor fluctuation without dyskinesia within 4 week immediately Screening , must experience minimum 2 hours/day `` '' time , Hoehn &amp; Yahr stage 2.5 4 `` '' state . Each participant , without help caregiver , must capable maintain accurate complete symptom diary adhere dose visit schedule . Each participant must result Screening clinical laboratory test draw within 5 week prior Randomization clinically acceptable investigator within parameter specify exclusion ( ) . All participant sexually active plan sexually active agree use highly effective method birth control study 2 week last dose study drug . A male participant must also donate sperm within 2 week last dose study drug . A participant must form drug induced atypical parkinsonism , cognitive impairment , bipolar disorder , untreated major depressive disorder , schizophrenia , psychotic disorder ; history exposure know neurotoxin , neurological feature consistent diagnosis PD assess investigator . A participant must history repeat stroke head injury , stroke within 6 month Screening ; poorly control diabetes ; abnormal renal function ; severe ongoing unstable medical condition . A participant must surgery PD . A participant must imminent risk selfharm harm others . A participant must systolic blood pressure ( BP ) ≥150 mm Hg OR diastolic BP ≥95 mm Hg Screening 2 BP rechecks prior study start . A participant must clinically significant cardiovascular event procedure 6 month prior study start , include , limited , myocardial infarction , angioplasty , unstable angina , heart failure ; participant must heart failure stag New York Heart Association Class III IV . A participant must alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥3 x upper limit normal ( ULN ) total bilirubin ( T BIL ) ≥1.5 x ULN . A participant must history serologically confirm hepatic dysfunction ( defined viral infection [ Hepatitis B , C , E ; EpsteinBarr virus ( EBV ) ; cytomegalovirus ( CMV ) ] ) history diagnosis drug alcohol induce hepatic toxicity frank hepatitis . A participant must history within past 5 year primary recurrent malignant disease exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ prostate cancer normal prostatespecific antigen ( PSA ) post resection . A participant must receive certain prespecified medication prespecified time window trial . A participant must average daily consumption three 4 ounce glass ( 118 mL ) wine equivalent . A participant must severe ongoing unstable medical condition ( eg , form clinically significant cardiac disease , symptomatic orthostatic hypotension , seizure , alcohol/drug dependence ) . A participant must allergy/sensitivity investigational product ( ) its/their excipients . A participant must breastfeed , consider breastfeeding , pregnant , intend become pregnant . A participant must use preladenant ever , investigational drug within 90 day immediately Screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>